Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study

Hereditary angioedema (HAE) is a rare disease caused by C1‐esterase inhibitor (C1‐INH) deficiency, characterized by periodic attacks of acute edema affecting subcutaneous (SC) tissues and mucous membranes. Human C1‐INH concentrate given intravenously (IV) is effective and safe, but venous access may be difficult. We compared SC and IV administration of human pasteurized C1‐INH concentrate with respect to pharmacokinetics, pharmacodynamics, and safety.

[1]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[2]  M. Cicardi,et al.  Hereditary angio-oedema , 2012, The Lancet.

[3]  S. Dychter,et al.  Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE) , 2012 .

[4]  K. Bork,et al.  Review of the Long-Term Safety of a Human Pasteurized C1 Inhibitor Concentrate , 2012 .

[5]  T. Machnig,et al.  C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.

[6]  K. Bork.  Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency , 2011, Expert review of clinical immunology.

[7]  J. Bernstein,et al.  Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  M. Frank,et al.  Subcutaneous infusion of human C1 inhibitor in swine. , 2010, Clinical immunology.

[9]  Thomas A McDonald,et al.  Subcutaneous administration of biotherapeutics: current experience in animal models. , 2010, Current opinion in molecular therapeutics.

[10]  J. Bernstein,et al.  Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[12]  K. Bork.  Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[13]  William H. Yang,et al.  Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema , 2010, Journal of Clinical Immunology.

[14]  A. Kaplan,et al.  The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  H. Ochs,et al.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease , 2010, Therapeutics and clinical risk management.

[16]  T. Klingebiel,et al.  Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study , 2010, Transfusion.

[17]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[18]  A. Davis.  Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  William H. Yang,et al.  Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Levi,et al.  Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. , 2006, The Journal of allergy and clinical immunology.

[21]  W. Jiskoot,et al.  Erythropoietin-Associated PRCA: Still an Unsolved Mystery , 2006, Journal of immunotoxicology.

[22]  H. Schellekens,et al.  Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview , 2005, Annals of the New York Academy of Sciences.

[23]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[24]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[25]  H. Farkas,et al.  Clinical management of hereditary angio‐oedema in children , 2002, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[26]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[27]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[28]  C. Hack,et al.  Inactivation of Factor XIa in Vivo: Studies in Chimpanzees and in Humans , 1996, Thrombosis and Haemostasis.

[29]  T. Mollnes,et al.  Activation of the Complement, Coagulation, Fibrinolytic and Kallikrein–Kinin Systems During Attacks of Hereditary Angioedema , 1996, Immunopharmacology.

[30]  M. Cicardi,et al.  Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. , 1996, Immunopharmacology.

[31]  T. Mollnes,et al.  Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. , 1996, Scandinavian journal of immunology.

[32]  F. Pavalko,et al.  Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  B. Lämmle,et al.  Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47 kDa light chain , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[34]  K. Bork,et al.  Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. , 1989, The Journal of allergy and clinical immunology.

[35]  B. Lämmle,et al.  Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI , 1988, Thrombosis and Haemostasis.

[36]  J. Curd,et al.  The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. , 1986, The Journal of allergy and clinical immunology.

[37]  B. Lämmle,et al.  Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. , 1986, Blood.

[38]  R. Bizios,et al.  Thrombin‐induced increase in albumin permeability across the endothelium , 1986, Journal of cellular physiology.

[39]  E. Dunsky,et al.  [Hereditary angio-edema]. , 1984, Harefuah.

[40]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.

[41]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.

[42]  F. Kueppers,et al.  Half‐life of CINH in hereditary angioneurotic oedema (HAE) * , 1975, Clinical allergy.

[43]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.